Home › Funds › Avoro Capital Advisors LLC › MDGL
Avoro Capital Advisors LLC position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
Avoro Capital Advisors LLC reported holding 1,833,333 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$923.9M, representing 9.56% of its reported portfolio and ranking #5 among its reported holdings. Avoro Capital Advisors LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's MDGL position evolved
Avoro Capital Advisors LLC first disclosed a stake in MDGL in Q3 2023 at 1,555,000 shares (US$227.1M). The position peaked in Q4 2025 at 1,807,500 shares, worth US$1.05B. Across 13 filings, Avoro Capital Advisors LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,833,333 shares valued at US$923.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.55M | $227.09M | New |
| Q4 2023 | 1.89M | $437.05M | Add |
| Q1 2024 | 1.94M | $519.24M | Add |
| Q2 2024 | 2.06M | $575.88M | Add |
| Q3 2024 | 2.03M | $430.59M | Reduce |
| Q4 2024 | 2.03M | $626.09M | Hold |
| Q1 2025 | 2.02M | $669.82M | Hold |
| Q2 2025 | 1.88M | $567.45M | Reduce |
| Q3 2025 | 1.83M | $840.72M | Reduce |
| Q4 2025 | 1.81M | $1.05B | Reduce |
| Q1 2026 | 1.82M | $951.76M | Add |
| Q2 2026 | 1.83M | $984.41M | Add |
| Q3 2026 | 1.83M | $923.93M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MDGL and 13F data
MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 45 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), Janus Henderson Group (US$1.05B), Jupiter Topco LLC (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MDGL
- BAKER BROS. ADVISORS LP 2.14M sh · $1.15B · Q2 2026
- Janus Henderson Group 2.02M sh · $1.05B · Q1 2026
- Jupiter Topco LLC 1.94M sh · $1.04B · Q2 2026
- Paulson & Co 1.34M sh · $719.52M · Q2 2026
- PAULSON & CO. INC. 1.34M sh · $719.52M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 337.04K sh · $169.85M · Q3 2026
- RTW INVESTMENTS, LP 312.82K sh · $157.65M · Q3 2026
- Rock Springs Capital Management LP 177.25K sh · $89.33M · Q3 2026
- Hood River Capital Management LLC 170.68K sh · $86.02M · Q3 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held MDGL?
Avoro Capital Advisors LLC has disclosed MDGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Avoro Capital Advisors LLC's current position in MDGL?
As of Q3 2026, Avoro Capital Advisors LLC holds 1.83M shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $923.93M, representing 9.56% of its reported portfolio and ranking #5.
Has Avoro Capital Advisors LLC been buying or selling MDGL?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC held unchanged its position in MDGL. The position peaked in Q4 2025 at 1.81M shares.
Which other funds hold MDGL?
Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, Janus Henderson Group, Jupiter Topco LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.